More than 15% of patients at risk for rare cancers missed screenings during COVID

CHICAGO — In rare hereditary cancers such as paraganglioma/pheochromocytoma, where patients travel for their care, COVID caused a disruption in their screening and treatments, according to a poster presented during ASCO Annual Meeting.
“Though up to 40% of paragangliomas and pheochromocytomas are due to a hereditary cause, this condition is still quite rare overall,” Samantha Greenberg, CGC, MPH, MS, of Huntsman Cancer Institute, University of Utah, said during her presentation. “As a result, oftentimes, patients travel to specialty care centers and, amidst COVID

CHICAGO — In rare hereditary cancers such as paraganglioma/pheochromocytoma, where patients travel for their care, COVID caused a disruption in their screening and treatments, according to a poster presented during ASCO Annual Meeting.
“Though up to 40% of paragangliomas and pheochromocytomas are due to a hereditary cause, this condition is still quite rare overall,” Samantha Greenberg, CGC, MPH, MS, of Huntsman Cancer Institute, University of Utah, said during her presentation. “As a result, oftentimes, patients travel to specialty care centers and, amidst COVID